Recent events
Recent events tied to this brand in public sources.
Back to profile81 entries · Page 2 of 5
2021
Pfizer sues former employee over alleged file downloads
Pfizer sued former employee Chun Xiao Li, alleging that she downloaded thousands of company files, including confidential information and trade secrets, to personal devices without permission. Pfizer sought a temporary restraining order and injunctive relief.
2021
Judge grants temporary restraining order requested by Pfizer
A U.S. district judge granted Pfizer's requested temporary restraining order and authorized the company's lawyers to review Li's accounts and devices. A hearing on a longer injunction was set for Dec. 9.
2021
Judge temporarily bars Pfizer employee from using trade secrets
A U.S. District Judge temporarily blocked Chun Xiao Li from using Pfizer's trade secrets and authorized Pfizer's lawyers to review accounts and devices where she might have stored them.
2021
FDA authorizes Pfizer and Moderna COVID-19 boosters for all adults
The FDA authorized COVID-19 booster shots for all adults from Pfizer and Moderna. The report said CDC action was still required before the shots could be administered to all adults.
2021
Pfizer completes acquisition of Trillium Therapeutics
Pfizer announced that it completed its acquisition of Trillium Therapeutics, which became a wholly owned subsidiary of Pfizer.
2021
Celcuity and Pfizer enter clinical trial collaboration and supply agreement
Celcuity announced a clinical trial collaboration and supply agreement with Pfizer, under which Pfizer will provide Ibrance (palbociclib) at no cost for Celcuity's planned Phase 3 clinical trial.
2021
Biohaven and Pfizer announce NURTEC ODT commercialization collaboration
Biohaven and Pfizer announced a strategic collaboration for the global commercialization of NURTEC ODT outside the United States. Biohaven is to receive double-digit royalties on ex-US net sales, an upfront payment and milestone value of up to $1.24 billion.
2021
Pfizer expands Chantix recall to all lots
Pfizer expanded the Chantix recall to all 156 lots of 0.5 mg and 1 mg tablets because of the potential presence of the nitrosamine impurity N-Nitroso-varenicline at or above the FDA interim acceptable intake limit. The FDA said long-term ingestion may be associated with a theoretical increased cancer risk; it also noted there was no immediate risk to patients.
2021
Pfizer recalls Chantix smoking-cessation drug
Pfizer announced a recall of its Champix (also called Chantix) smoking-cessation drugs, saying they contain chemicals that cause cancer.
2021
FDA fully approves Pfizer/BioNTech COVID-19 vaccine
The FDA fully approved Pfizer/BioNTech's COVID-19 vaccine on August 23, 2021; the vaccine will be marketed as Comirnaty for prevention of COVID-19 in individuals aged 16 and older.
2021
FDA approves Pfizer vaccine for people 16 and older
The U.S. Food and Drug Administration approved the Pfizer vaccine for people 16 and older, moving it from emergency-use status.
2021
Pfizer announces proposed acquisition of Trillium Therapeutics
Pfizer announced that it plans to acquire the remainder of Trillium Therapeutics’ shares for $18.50 each, in a deal valued at $2.3 billion.
2021
Pfizer reports second-quarter 2021 results
Pfizer released its second-quarter 2021 financial results, reporting revenue of $18.977 billion, up 92% year over year, and net income attributable to common shareholders of $5.563 billion, up 59%.
2021
Pfizer and BioNTech sign vaccine manufacturing letter of intent with Biovac
Pfizer and BioNTech signed a letter of intent with Biovac Institute to manufacture their COVID-19 vaccine at Biovac's Cape Town facility. The companies said the facility was expected to join their supply chain by the end of 2021, with finished-dose production planned to begin in 2022.
2021
Pfizer recalls selected Chantix lots over possible impurity risk
Pfizer recalled a dozen US lots of Chantix after they were found to potentially contain N-nitroso-varenicline above the company's acceptable daily intake limit. The article says prolonged ingestion of high quantities could potentially lead to cancer; Pfizer stated there was no immediate risk to patients and advised users to discuss replacement with a health care provider or pharmacy.
2021
Pfizer recalls 12 distributed lots of Chantix
Pfizer recalled 12 additional lots of Chantix that had been distributed to wholesalers in the United States and Puerto Rico, after finding nitrosamine levels above the company’s acceptable daily intake level.
2021
Pfizer plaintiffs sue Qilu over Ibrance patent
Pfizer and co-plaintiffs filed suit against Qilu in the District of Delaware, seeking a declaration of patent infringement and an order barring further infringement. The complaint concerns the patent for Ibrance; the infringement claims are allegations in the lawsuit.
2021
Pfizer sues MSN Pharmaceuticals over palbociclib patent
Pfizer filed a lawsuit against MSN Pharmaceuticals, alleging that MSN's proposed generic palbociclib would infringe Pfizer's patent. The source describes the infringement as an allegation, not a court determination.
2021
Zipline and Pfizer partner on vaccine distribution solution
Zipline partnered with Pfizer to test and develop an end-to-end distribution solution for COVID-19 vaccines.
2021
FDA approves Pfizer’s PREVNAR 20 for adults
The U.S. Food and Drug Administration approved Pfizer’s PREVNAR 20 vaccine for adults aged 18 years and older to prevent invasive disease and pneumonia caused by the 20 pneumococcal serotypes included in the vaccine.